Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

Drug Resistance Updates

Volumn 16, Issue 6, 2013, Pages 81-95

  Arendrup, Maiken C ^a   Cuenca Estrella, Manuel ^b   Lass Flörl, Cornelia ^c   Hope, William W ^d  

^a STATENS SERUM INSTITUT   (Denmark)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Acquired resistance; Aspergillus; Azoles; Breakpoints; Candida; CLSI; Echinocandins; EUCAST; MIC; Susceptibility testing

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

AMINO ACID SEQUENCE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL SUSCEPTIBILITY TESTING; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MONITORING; DRUG TREATMENT FAILURE; ESOPHAGUS CANDIDIASIS; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIMULATION; TABLET FORMULATION; TREATMENT OUTCOME; ANIMAL; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

EID: 84900829814     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.01.001     Document Type: Review

References (132)

1. M.A. AbuTarif, G. Krishna, and P. Statkevich Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome Curr. Med. Res. Opin. 26 2010 397 405
2. A. Alanio, E. Sitterle, M. Liance, C. Farrugia, F. Foulet, F. Botterel, Y. Hicheri, C. Cordonnier, J.M. Costa, and S. Bretagne Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies J. Antimicrob. Chemother. 66 2011 371 374
3. D. Andes In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis Antimicrob. Agents Chemother. 47 2003 1179 1186
4. D. Andes Pharmacokinetics and pharmacodynamics in the development of antifungal compounds Curr. Opin. Investig. Drugs 4 2003 991 998
5. D. Andes, P.G. Ambrose, J.P. Hammel, S.A. Van Wart, V. Iyer, D.K. Reynolds, D.N. Buell, L.L. Kovanda, and S.M. Bhavnani Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia Antimicrob. Agents Chemother. 55 2011 2113 2121
6. D. Andes, D.J. Diekema, M.A. Pfaller, J. Bohrmuller, K. Marchillo, and A. Lepak In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species Antimicrob. Agents Chemother. 54 2010 2497 2506
7. D. Andes, D.J. Diekema, M.A. Pfaller, R.A. Prince, K. Marchillo, J. Ashbeck, and J. Hou In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model Antimicrob. Agents Chemother. 52 2008 539 550
8. D.R. Andes, D.J. Diekema, M.A. Pfaller, K. Marchillo, and J. Bohrmueller In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model Antimicrob. Agents Chemother. 52 2008 3497 3503
9. D.R. Andes, N. Safdar, J.W. Baddley, G. Playford, A.C. Reboli, J.H. Rex, J.D. Sobel, P.G. Pappas, and B.J. Kullberg Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials Clin. Infect. Dis. 54 2012 1110 1122
10. M. Arendrup, T. Horn, and N. Frimodt-Moller In vivo pathogenicity of eight medically relevant Candida species in an animal model Infection 30 2002 286 291
11. M.C. Arendrup Epidemiology of invasive candidiasis Curr. Opin. Crit. Care 16 2010 445 452
12. M.C. Arendrup Candida and candidaemia: susceptibility and epidemiology Dan. Med. J. 60 2013 B4698
13. M.C. Arendrup, M. Cuenca-Estrella, J.P. Donnelly, C. Lass-Florl, and J.L. Rodriguez-Tudela Association of fluconazole pharmacodynamics with mortality in patients with candidemia Antimicrob. Agents Chemother. 53 2009 2704 2705
14. M.C. Arendrup, M. Cuenca-Estrella, C. Lass-Florl, and W. Hope EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST) Clin. Microbiol. Infect. 18 2012 E246 E247
15. M.C. Arendrup, M. Cuenca-Estrella, C. Lass-Flörl, and W.W. Hope The European Committee on Antimicrobial Susceptibility Testing subcommittee on antifungal susceptibility testing (EUCAST-AFST) EUCAST technical note on Aspergillus and amphotericin-B, itraconazole, and posaconazole Clin. Microbiol. Infect. 17 2012 E248 E250
16. M.C. Arendrup, E. Dzajic, R.H. Jensen, H.K. Johansen, P. Kjældgaard, J.D. Knudsen, L. Kristensen, C. Leitz, L.E. Lemming, L. Nielsen, B. Olesen, F.S. Rosenvinge, B.L. Røder, and H.C. Schonheyder Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme Clin. Microbiol. Infect. 19 2013 E343 E353
17. M.C. Arendrup, G. Garcia-Effron, W. Buzina, K.L. Mortensen, N. Reiter, C. Lundin, H.E. Jensen, C. Lass-Florl, D.S. Perlin, and B. Bruun Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing Antimicrob. Agents Chemother. 53 2009 1185 1193
18. M.C. Arendrup, G. Garcia-Effron, C. Lass-Florl, A.G. Lopez, J.L. Rodriguez-Tudela, M. Cuenca-Estrella, and D.S. Perlin Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media Antimicrob. Agents Chemother. 54 2010 426 439
19. M.C. Arendrup, G. Kahlmeter, J.L. Rodriguez-Tudela, and J.P. Donnelly Breakpoints for susceptibility testing should not divide wild-type distributions of important target species Antimicrob. Agents Chemother. 53 2009 1628 1629
20. M.C. Arendrup, E. Mavridou, K.L. Mortensen, E. Snelders, N. Frimodt-Moller, H. Khan, W.J. Melchers, and P.E. Verweij Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence PLoS One 5 2010 e10080
21. M.C. Arendrup, D.S. Perlin, R.H. Jensen, S.J. Howard, J. Goodwin, and W. Hope Differential in vivo activity of anidulafungin caspofungin and micafungin against C. glabrata with and without FKS resistance mutations Antimicrob. Agents Chemother. 56 2012 2435 2442
22. M.C. Arendrup, and M.A. Pfaller Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints Antimicrob. Agents Chemother. 56 2012 3965 3968
23. M.C. Arendrup, J.L. Rodriguez-Tudela, S. Park, G. Garcia-Effron, G. Delmas, M. Cuenca-Estrella, L.A. Gomez, and D.S. Perlin Echinocandin susceptibility testing of Candida spp. using the EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time and drug lots Antimicrob. Agents Chemother. 55 2011 1580 1587
24. M.C. Arendrup, S. Sulim, A. Holm, L. Nielsen, S.D. Nielsen, J.D. Knudsen, N.E. Drenck, J.J. Christensen, and H.K. Johansen Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia J. Clin. Microbiol. 49 2011 3300 3308
25. M.C. Arendrup, M. Cuenca-Estrella, C. Lass-Flörl, and W.W. Hope The European Committee on Antimicrobial Susceptibility Testing-subcommittee on antifungal susceptibility testing (EUCAST-AFST). EUCAST technical note on Candida and Micafungin, Anidulafungin and Fluconazole Mycoses 2014 10.1111/myc.12170 (in press)
26. S. Arikan-Akdagli Azole resistance in Aspergillus: global status in Europe and Asia Ann. N. Y. Acad. Sci. 1272 2012 9 14
27. K.M. Astvad, D.S. Perlin, H.K. Johansen, R.H. Jensen, and M.C. Arendrup Evaluation of caspofungin susceptibility testing by the new vitek 2 AST-YS06 yeast card using a unique collection of fks wild-type and hot spot mutant isolates including the five most common Candida species Antimicrob. Agents Chemother. 57 2013 177 182
28. M. Axner-Elings, S. Botero-Kleiven, R.H. Jensen, and M.C. Arendrup Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden J. Clin. Microbiol. 49 2011 2516 2521
29. M.A. Boogaerts, G.E. Verhoef, P. Zachee, H. Demuynck, L. Verbist, and K. De Beule Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels Mycoses 32 Suppl. 1 1989 103 108
30. A. Bueid, S.J. Howard, C.B. Moore, M.D. Richardson, E. Harrison, P. Bowyer, and D.W. Denning Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009 J. Antimicrob. Chemother. 65 2010 2116 2118
31. D. Caillot, H. Bassaris, A. McGeer, C. Arthur, H.G. Prentice, W. Seifert, and B.K. De Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS Clin. Infect. Dis. 33 2001 e83 e90
32. P. Campoli, A.Q. Al, R. Robitaille, N.V. Solis, J.A. Fielhaber, A.S. Kristof, M. Laverdiere, S.G. Filler, and D.C. Sheppard Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis Antimicrob. Agents Chemother. 55 2011 5732 5739
33. P. Campoli, D.S. Perlin, A.S. Kristof, T.C. White, S.G. Filler, and D.C. Sheppard Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis J. Infect. Dis. 208 2013 1717 1728
34. S.M.T. Camps, B.E. Dutilh, M.C. Arendrup, A.J.M.M. Rijs, E. Snelders, M.A. Huynen, P.E. Verweij, and W.J.G. Melchers Discovery of a hapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing PLoS One 7 2012 e50034
35. S.M.T. Camps, J.W.M. van der Linden, Y. Li, E.J. Kuijper, J.T. van Dissel, P.E. Verweij, and W.J.G. Melchers Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature Antimicrob. Agents Chemother. 56 2012 10 16
36. A. Chowdhary, S. Kathuria, H.S. Randhawa, S.N. Gaur, C.H. Klaassen, and J.F. Meis Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India J. Antimicrob. Chemother. 67 2012 362 366
37. Clinical and Laboratory Standards Institute (CLSI) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Third edition. CLSI Document M27-A3 2008 Clinical and laboratory Standards Institute Pennsylvania, USA
38. Clinical Laboratory Standards Institute (CLSI) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard - Second Edition. NCCLS Document M38-A2 2008 Clinical Laboratory Standards Institute Wayne, Pennsylvania
39. O.A. Cornely, M. Bassetti, T. Calandra, J. Garbino, B.J. Kullberg, O. Lortholary, W. Meersseman, M. Akova, M.C. Arendrup, S. Arikan-Akdagli, J. Bille, E. Castagnola, M. Cuenca-Estrella, J. Peter Donnelly, A.H. Groll, R. Herbrecht, W.W. Hope, H.E. Jensen, C. Lass-FlÂrl, G. Petrikkos, M.D. Richardson, E. Roilides, P.E. Verweij, C. Viscoli, and A.J. Ullmann ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients Clin. Microbiol. Infect. 18 2012 19 37
40. O.A. Cornely, J. Maertens, D.J. Winston, J. Perfect, A.J. Ullmann, T.J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y.T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia N. Engl. J. Med. 356 2007 348 359
41. M. Cuenca-Estrella, A. Gomez-Lopez, A. Alastruey-Izquierdo, L. Bernal-Martinez, I. Cuesta, M.J. Buitrago, and J.L. Rodriguez-Tudela Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth microdilution reference methods and with the sensititre yeast one and Etest techniques for in vitro detection of antifungal resistance in yeast isolates J. Clin. Microbiol. 48 2010 1782 1786
42. M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, and J.L. Rodriguez-Tudela Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques Clin. Microbiol. Infect. 11 2005 486 492
43. M. Cuenca-Estrella, P.E. Verweij, M.C. Arendrup, S. Arikan-Akdagli, J. Bille, J.P. Donnelly, H.E. Jensen, C. Lass-FlÂrl, M.D. Richardson, M. Akova, M. Bassetti, T. Calandra, E. Castagnola, O.A. Cornely, J. Garbino, A.H. Groll, R. Herbrecht, W.W. Hope, B.J. Kullberg, O. Lortholary, W. Meersseman, G. Petrikkos, E. Roilides, C. Viscoli, A.J. Ullmann, and The ESCMID Fungal Infection Study Group ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures Clin. Microbiol. Infect. 18 2012 9 18
44. E. Dannaoui, M. Desnos-Ollivier, D. Garcia-Hermoso, F. Grenouillet, S. Cassaing, M.T. Baixench, S. Bretagne, F. Dromer, and O. Lortholary Candida spp. with acquired echinocandin resistance France, 2004-2010 Emerg. Infect. Dis. 18 2012 86 90
45. K. De Beule, and J. Van Gestel Pharmacology of itraconazole Drugs 61 Suppl. 1 2001 27 37
46. D.W. Denning, J.Y. Lee, J.S. Hostetler, P. Pappas, C.A. Kauffman, D.H. Dewsnup, J.N. Galgiani, J.R. Graybill, A.M. Sugar, and A. Catanzaro NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis Am. J. Med. 97 1994 135 144
47. D.W. Denning, and D.S. Perlin Azole resistance in Aspergillus: a growing public health menace Future Microbiol. 6 2011 1229 1232
48. D.W. Denning, K. Riniotis, R. Dobrashian, and H. Sambatakou Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review Clin. Infect. Dis. 37 Suppl. 3 2003 S265 S280
49. D.W. Denning, R.M. Tucker, L.H. Hanson, and D.A. Stevens Treatment of invasive aspergillosis with itraconazole Am. J. Med. 86 1989 791 800
50. D.W. Denning, K. Venkateswarlu, K.L. Oakley, M.J. Anderson, N.J. Manning, D.A. Stevens, D.W. Warnock, and S.L. Kelly Itraconazole resistance in Aspergillus fumigatus Antimicrob. Agents Chemother. 41 1997 1364 1368
51. T.M. Diaz-Guerra, E. Mellado, M. Cuenca-Estrella, and J.L. Rodriguez-Tudela A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus Antimicrob. Agents Chemother. 47 2003 1120 1124
52. C. Eiden, J. Meniane, H. Peyriere, S. Eymard-Duvernay, G. Le Falher, P. Ceballos, N. Fegueux, M. Cociglio, J. Reynes, and D. Hillaire-Buys Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake Eur. J. Clin. Microbiol. Infect. Dis. 31 2012 161 167
53. A. Espinel-Ingroff, M.C. Arendrup, M.A. Pfaller, L.X. Bonfietti, B. Bustamante, E. Canton, E. Chryssanthou, M. Cuenca-Estrella, E. Dannaoui, A. Fothergill, J. Fuller, P. Gaustad, G.M. Gonzalez, J. Guarro, C. Lass-Florl, S.R. Lockhart, J.F. Meis, C.B. Moore, L. Ostrosky-Zeichner, T. Pelaez, S.R. Pukinskas, G. St-Germain, M.W. Szeszs, and J. Turnidge Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57 2013 5836 5842
54. A. Espinel-Ingroff, E. Canton, J. Peman, and E. Martin-Mazuelo Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates Antimicrob. Agents Chemother. 54 2010 1347 1350
55. A. Fekkar, I. Meyer, J.Y. Brossas, E. Dannaoui, M. Palous, M. Uzunov, S. Nguyen, V. Leblond, D. Mazier, and A. Datry Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin Antimicrob. Agents Chemother. 57 2013 2380 2382
56. G.N. Forrest, E. Weekes, and J.K. Johnson Increasing incidence of Candida parapsilosis candidemia with caspofungin usage J. Infect. 56 2008 126 129
57. M.G. Fraczek, M. Bromley, A. Buied, C.B. Moore, R. Rajendran, R. Rautemaa, G. Ramage, D.W. Denning, and P. Bowyer The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus J. Antimicrob. Chemother. 68 2013 1486 1496
58. G. Garcia-Effron, D.J. Chua, J.R. Tomada, J. Dipersio, D.S. Perlin, M. Ghannoum, and H. Bonilla Novel FKS mutations associated with echinocandin resistance in Candida species Antimicrob. Agents Chemother. 54 2010 2225 2227
59. G. Garcia-Effron, S.K. Katiyar, S. Park, T.D. Edlind, and D.S. Perlin A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility Antimicrob. Agents Chemother. 52 2008 2305 2312
60. G. Garcia-Effron, S. Lee, S. Park, J.D. Cleary, and D.S. Perlin Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-{beta}-d-glucan synthase: implication for the existing susceptibility breakpoint Antimicrob. Agents Chemother. 53 2009 3690 3699
61. G. Garcia-Effron, S. Park, and D.S. Perlin Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints Antimicrob. Agents Chemother. 53 2009 112 122
62. K.W. Garey, M. Rege, M.P. Pai, D.E. Mingo, K.J. Suda, R.S. Turpin, and D.T. Bearden Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study Clin. Infect. Dis. 43 2006 25 31
63. S.P. Georgiadou, and D.P. Kontoyiannis The impact of azole resistance on aspergillosis guidelines Ann. N. Y. Acad. Sci. 1272 2012 15 22
64. A. Glasmacher, C. Hahn, C. Leutner, E. Molitor, E. Wardelmann, C. Losem, T. Sauerbruch, G. Marklein, and I.G. Schmidt-Wolf Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole Mycoses 42 1999 443 451
65. G.E. Hayes, and D.W. Denning Frequency, diagnosis and management of fungal respiratory infections Curr. Opin. Pulm. Med. 19 2013 259 265
66. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.W. Oestmann, W.V. Kern, K.A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R.H. Rubin, J.R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P.H. Chandrasekar, M.R. Hodges, H.T. Schlamm, P.F. Troke, and P.B. de Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N. Engl. J. Med. 347 2002 408 415
67. W.W. Hope Population pharmacokinetics of voriconazole in adults Antimicrob. Agents Chemother. 56 2012 526 531
68. W.W. Hope, E. Castagnola, A.H. Groll, E. Roilides, M. Akova, M.C. Arendrup, S. Arikan-Akdagli, M. Bassetti, J. Bille, O.A. Cornely, M. Cuenca-Estrella, J. Peter Donnelly, J. Garbino, R. Herbrecht, H.E. Jensen, B.J. Kullberg, C. Lass-FlÂrl, O. Lortholary, W. Meersseman, G. Petrikkos, M.D. Richardson, P.E. Verweij, C. Viscoli, A.J. Ullmann The ESCMID Fungal Infection Study Group ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin. Microbiol. Infect. 18 2012 38 52
69. S.J. Howard, D. Cerar, M.J. Anderson, A. Albarrag, M.C. Fisher, A.C. Pasqualotto, M. Laverdiere, M.C. Arendrup, D.S. Perlin, and D.W. Denning Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure Emerg. Infect. Dis. 15 2009 1068 1076
70. S.J. Howard, T.W. Felton, A. Gomez-Lopez, and W.W. Hope Posaconazole: the case for therapeutic drug monitoring Ther. Drug Monit. 34 2012 72 76
71. S.J. Howard, C. Lass-Florl, M. Cuenca-Estrella, A. Gomez-Lopez, and M.C. Arendrup Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method Antimicrob. Agents Chemother. 57 2013 5426 5431
72. S.J. Howard, J.M. Lestner, A. Sharp, L. Gregson, J. Goodwin, J. Slater, J.B. Majithiya, P.A. Warn, and W.W. Hope Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy J. Infect. Dis. 203 2011 1324 1332
73. S.J. Howard, J. Livermore, A. Sharp, J. Goodwin, L. Gregson, A. Alastruey-Izquierdo, D.S. Perlin, P.A. Warn, and W.W. Hope Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts Antimicrob. Agents Chemother. 55 2011 4880 4887
74. S.J. Howard, and M.C. Arendrup Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection Med. Mycol. 49 Suppl. 1 2011 90 95
75. S.H. Jang, P.M. Colangelo, and J.V. Gobburu Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma Clin. Pharmacol. Ther. 88 2010 115 119
76. A.R. Jeans, S.J. Howard, Z. Al-Nakeeb, J. Goodwin, L. Gregson, J.B. Majithiya, C. Lass-Florl, M. Cuenca-Estrella, M.C. Arendrup, P.A. Warn, and W.W. Hope Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints J. Infect. Dis. 206 2012 442 452
77. R.H. Jensen, and M.C. Arendrup Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species J. Clin. Microbiol. 49 2011 549 556
78. R.H. Jensen, H.K. Johansen, and M.C. Arendrup Stepwise development of a homozygous S80P substitution in fks1p conferring echinocandin resistance in Candida tropicalis Antimicrob. Agents Chemother. 57 2013 614 617
79. G. Kahlmeter, D.F. Brown, F.W. Goldstein, A.P. MacGowan, J.W. Mouton, A. Osterlund, A. Rodloff, M. Steinbakk, P. Urbaskova, and A. Vatopoulos European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria J. Antimicrob. Chemother. 52 2003 145 148
80. G. Krishna, L. Ma, M. Martinho, and E. O'Mara Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension Antimicrob. Agents Chemother. 56 2012 4196 4201
81. G. Krishna, A. Moton, L. Ma, M.M. Medlock, and J. McLeod Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob. Agents Chemother. 53 2009 958 966
82. S. Kuipers, R.J. Bruggemann, R.G. de Sevaux, J.P. Heesakkers, W.J. Melchers, J.W. Mouton, and P.E. Verweij Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole Antimicrob. Agents Chemother. 55 2011 3564 3566
83. E.R. Kuse, P. Chetchotisakd, C.A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J.S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A.J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O.A. Cornely Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
84. C. Lass-Flörl, M.C. Arendrup, J.L. Rodriguez-Tudela, M. Cuenca-Estrella, P. Donnelly, and W. Hope The European committee on antimicrobial susceptibility testing ΓÇô subcommittee on antifungal susceptibility testing (EUCAST-AFST) EUCAST Technical note on Amphotericin B Clin. Microbiol. Infect. 17 2011 E27 E29
85. J. Lestner, and W.W. Hope Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections Expert Opin. Drug Metab. Toxicol. 9 2013 911 926
86. S.R. Lockhart, J.P. Frade, K.A. Etienne, M.A. Pfaller, D.J. Diekema, and S.A. Balajee Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene Antimicrob. Agents Chemother. 55 2011 4465 4468
87. O. Lortholary, M. Desnos-Ollivier, K. Sitbon, A. Fontanet, S. Bretagne, and F. Dromer Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients Antimicrob. Agents Chemother. 55 2011 532 538
88. O. Lortholary, G. Petrikkos, M. Akova, M.C. Arendrup, S. Arikan-Akdagli, M. Bassetti, J. Bille, E. Castagnola, O.A. Cornely, M. Cuenca-Estrella, J. Peter Donnelly, J. Garbino, A.H. Groll, R. Herbrecht, W.W. Hope, H.E. Jensen, B.J. Kullberg, C. Lass-FlÂrl, W. Meersseman, M.D. Richardson, E. Roilides, P.E. Verweij, C. Viscoli, A.J. Ullmann The ESCMID Fungal Infection Study Group ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS Clin. Microbiol. Infect. 18 2012 68 77
89. E. Mavridou, R.J. Bruggemann, W.J. Melchers, J.W. Mouton, and P.E. Verweij Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene Antimicrob. Agents Chemother. 54 2010 860 865
90. E. Mellado, G. Garcia-Effron, L. Alcazar-Fuoli, W.J. Melchers, P.E. Verweij, M. Cuenca-Estrella, and J.L. Rodriguez-Tudela A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations Antimicrob. Agents Chemother. 51 2007 1897 1904
91. K.L. Mortensen, E. Mellado, C. Lass-Florl, J.L. Rodriguez-Tudela, H.K. Johansen, and M.C. Arendrup Environmental study of azole-resistant Aspergillus fumigatus and other Aspergilli in Austria, Denmark, and Spain Antimicrob. Agents Chemother. 54 2010 4545 4549
92. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr., T.F. Calandra, J.E. Edwards Jr., S.G. Filler, J.F. Fisher, B.J. Kullberg, L. Ostrosky-Zeichner, A.C. Reboli, J.H. Rex, T.J. Walsh, and J.D. Sobel Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin. Infect. Dis. 48 2009 503 535
93. P.G. Pappas, C.M. Rotstein, R.F. Betts, M. Nucci, D. Talwar, J.J. De Waele, J.A. Vazquez, B.F. Dupont, D.L. Horn, L. Ostrosky-Zeichner, A.C. Reboli, B. Suh, R. Digumarti, C. Wu, L.L. Kovanda, L.J. Arnold, and D.N. Buell Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis Clin. Infect. Dis. 45 2007 883 893
94. A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin. Infect. Dis. 46 2008 201 211
95. P. Pechlivanoglou, H.H. Le, S. Daenen, J.A. Snowden, and M.J. Postma Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review J. Antimicrob. Chemother. 69 2014 1 11
96. S. Perkhofer, V. Lechner, and C. Lass-Florl In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing Antimicrob. Agents Chemother. 53 2009 1645 1647
97. D.S. Perlin Resistance to echinocandin-class antifungal drugs Drug Resist. Updat. 10 2007 121 130
98. M.A. Pfaller, M. Castanheira, D.J. Diekema, S.A. Messer, G.J. Moet, and R.N. Jones Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species J. Clin. Microbiol. 48 2010 1592 1599
99. M.A. Pfaller, M. Castanheira, S.R. Lockhart, A.M. Ahlquist, S.A. Messer, and R.N. Jones Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata J. Clin. Microbiol. 50 2012 1199 1203
100. M.A. Pfaller, V. Chaturvedi, D.J. Diekema, M.A. Ghannoum, N.M. Holliday, S.B. Killian, C.C. Knapp, S.A. Messer, A. Miskou, and R. Ramani Comparison of the sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values Diagn. Microbiol. Infect. Dis. 73 2012 365 368
101. M.A. Pfaller, D.J. Diekema, D. Andes, M.C. Arendrup, S.D. Brown, S.R. Lockhart, M. Motyl, and D.S. Perlin Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria Drug Resist. Updat. 14 2011 164 176
102. M.A. Pfaller, S.A. Messer, P.R. Rhomberg, R.N. Jones, and M. Castanheira In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds J. Clin. Microbiol. 51 2013 2608 2616
103. C.D. Pfeiffer, G. Garcia-Effron, A.K. Zaas, J.R. Perfect, D.S. Perlin, and B.D. Alexander Breakthrough invasive candidiasis in patients on micafungin J. Clin. Microbiol. 48 2010 2373 2380
104. J.M. Poirier, F. Berlioz, F. Isnard, and G. Cheymol Marked intra- and inter-patient variability of itraconazole steady state plasma concentrations Therapie 51 1996 163 167
105. J.M. Poirier, and G. Cheymol Optimisation of itraconazole therapy using target drug concentrations Clin. Pharmacokinet. 35 1998 461 473
106. J.M. Poirier, S. Hardy, F. Isnard, P. Tilleul, J. Weissenburger, and G. Cheymol Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen Ther. Drug Monit. 19 1997 525 529
107. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, D. Kumar, R. Betts, M. Wible, B.P. Goldstein, J. Schranz, D.S. Krause, and T.J. Walsh Anidulafungin versus fluconazole for invasive candidiasis N. Engl. J. Med. 356 2007 2472 2482
108. J.L. Rodriguez-Tudela, B. Almirante, D. Rodriguez-Pardo, F. Laguna, J.P. Donnelly, J.W. Mouton, A. Pahissa, and M. Cuenca-Estrella Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia Antimicrob. Agents. Chemother. 51 2007 3599 3604
109. J.L. Rodriguez-Tudela, M.C. Arendrup, S. Arikan, F. Barchisei, J. Bille, E. Chryssantou, M. Cuenca-Estrella, E. Dannaoui, D.W. Denning, J.P. Donnellly, W. Fegeler, C. Lass-Flörl, C. Moore, M. Richardson, P. Gaustad, A. Schmalreck, A. Velegraki, and P. Verweij EUCAST Technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds Clin. Microbiol. Infect. 14 2008 982 984
110. J.L. Rodriguez-Tudela, M.C. Arendrup, M. Cuenca-Estrella, J.P. Donnelly, and C. Lass-Floerl EUCAST breakpoints for antifungals Drug News Perspect. 23 2010 93 97
111. R.K. Shields, M.H. Nguyen, E.G. Press, A.L. Kwa, S. Cheng, C. Du, and C.J. Clancy The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata Antimicrob. Agents Chemother. 56 2012 4862 4869
112. R.K. Shields, M.H. Nguyen, E.G. Press, C.L. Updike, and C.J. Clancy Anidulafungin and micafungin minimum inhibitory concentration breakpoints are superior to caspofungin for identifying FKS mutant Candida glabrata and echinocandin resistance Antimicrob. Agents Chemother. 57 2013 6361 6365
113. R.K. Shields, M.H. Nguyen, E.G. Press, C.L. Updike, and C.J. Clancy Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure Antimicrob. Agents Chemother. 57 2013 3528 3535
114. N.V. Sipsas, R.E. Lewis, J. Tarrand, R. Hachem, K.V. Rolston, I.I. Raad, and D.P. Kontoyiannis Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection Cancer 115 2009 4745 4752
115. J.L. Slater, S.J. Howard, A. Sharp, J. Goodwin, L.M. Gregson, A. Alastruey-Izquierdo, M.C. Arendrup, P.A. Warn, D.S. Perlin, and W.W. Hope Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin Antimicrob. Agents Chemother. 55 2011 3075 3083
116. E. Snelders, W.J. Melchers, and P.E. Verweij Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol. 6 2011 335 347
117. E. Snelders, H.A. van der Lee, J. Kuijpers, A.J. Rijs, J. Varga, R.A. Samson, E. Mellado, A.R. Donders, W.J. Melchers, and P.E. Verweij Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism PLoS Med. 5 2008 e219
118. E. Snelders, R. Huis in't Veld, A.J.M.M. Rijs, G.H.J. Kema, W.J.G. Melchers, and P.E. Verweij Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles Appl. Environ. Microbiol. 75 2009 4053 4057
119. E. Snelders, A. Karawajczyk, R.J.A. Verhoeven, H. Venselaar, G. Schaftenaar, P.E. Verweij, and W.J.G. Melchers The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance Fungal Genet. Biol. 48 2011 1062 1070
120. C.R. Stensvold, L.N. Jørgensen, and M.C. Arendrup Azole-resistant invasive Aspergillosis: relationship to agriculture Curr. Fungal Infect. Rep. 6 2012 178 191
121. Subcommittee on antifungal susceptibility testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), EUCAST technical note on voriconazole Clin. Microbiol. Infect. 14 2008 985 987
122. P.F. Troke, H.P. Hockey, and W.W. Hope Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients Antimicrob. Agents Chemother. 55 2011 4782 4788
123. J. Turnidge, G. Kahlmeter, and G. Kronvall Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values Clin. Microbiol. Infect. 12 2006 418 425
124. A.J. Ullmann, M. Akova, R. Herbrecht, C. Viscoli, M.C. Arendrup, S. Arikan-Akdagli, M. Bassetti, J. Bille, T. Calandra, E. Castagnola, O.A. Cornely, J. Peter Donnelly, J. Garbino, A.H. Groll, W.W. Hope, H.E. Jensen, B.J. Kullberg, C. Lass-FlÂrl, O. Lortholary, W. Meersseman, G. Petrikkos, M.D. Richardson, E. Roilides, P.E. Verweij, M. Cuenca-Estrella The ESCMID Fungal Infection Study Group ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT) Clin. Microbiol. Infect. 18 2012 53 67
125. J.W.M. van der Linden, S.M.T. Camps, G.A. Kampinga, J.P.A. Arends, Y.J. Debets-Ossenkopp, P.J.A. Haas, B.J.A. Rijnders, E.J. Kuijper, F.H. van Tiel, J. Varga, A. Karawajczyk, J. Zoll, W.J.G. Melchers, and P.E. Verweij Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles Clin. Infect. Dis. 57 2013 513 520
126. J.W.M. van der Linden, R.R. Jansen, D. Bresters, C.E. Visser, S.E. Geerlings, E.J. Kuijper, W.J.G. Melchers, and P.E. Verweij Azole-resistant central nervous system aspergillosis Clin. Infect. Dis. 48 2009 1111 1113
127. E. Vermeulen, S. Cooreman, J. Maertens, A. Jeurissen, and K. Lagrou Azole resistance in Aspergillus: an emerging problem? Acta Clin. Belg. 67 2012 322 327
128. P.E. Verweij, S.J. Howard, W.J. Melchers, and D.W. Denning Azole-resistance in Aspergillus: proposed nomenclature and breakpoints Drug Resist. Updat. 12 2009 141 147
129. P.E. Verweij, E. Snelders, G.H. Kema, E. Mellado, and W.J. Melchers Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect. Dis. 9 2009 789 795
130. T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, K.A. Marr, V.A. Morrison, B.H. Segal, W.J. Steinbach, D.A. Stevens, J.A. van Burik, J.R. Wingard, and T.F. Patterson Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin. Infect. Dis. 46 2008 327 360
131. T.J. Walsh, I. Raad, T.F. Patterson, P. Chandrasekar, G.R. Donowitz, R. Graybill, R.E. Greene, R. Hachem, S. Hadley, R. Herbrecht, A. Langston, A. Louie, P. Ribaud, B.H. Segal, D.A. Stevens, J.A. van Burik, C.S. White, G. Corcoran, J. Gogate, G. Krishna, L. Pedicone, C. Hardalo, and J.R. Perfect Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin. Infect. Dis. 44 2007 2 12
132. L. Willems, R. van der Geest, and B.K. De Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics J. Clin. Pharm. Ther. 26 2001 159 169